lotsa, your analysis is spot on. You are not negative at all, this is a realistic aspect of the pharma market seen with every company and the products they produce and sell. Right now is the perfect time for SCRC to maximize this compounding opportunity before any 3rd party reimbursement controls take effect. However, even then, compounding will still be a very profitable venture. I also agree that Mr. Schneiderman is aware of the market dynamics and will be positioning SCRC as a formidable competitor in the compounding marketplace. Thanks for your comments and I look forward to reading more of your insights.

BTW, your background and experience in the pharma industry once again adds to the incredible integrity, professionalism, and experience the CORE has as an SCRC investing group.